The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl).
OBJECTIVE
To assess whether tibolone can prevent the bone loss and symptomatic side effects normally associated with GnRH agonist (GnRH-a) use and whether tibolone modifies the effect of GnRH-a on endometriosis.


METHODS
Prospective, double-blind, placebo-controlled, group comparative study.


METHODS
Gynecological research unit in a London teaching hospital.


METHODS
Twenty-nine patients with endometriosis and two with fibroids.


METHODS
Six months of treatment with 3.75 mg/mo IM triptorelin combined with daily tablets of either placebo or 2.5 mg tibolone.


METHODS
Daily symptom diary for hot flushes and bleeding episodes, laparoscopic scoring of endometriosis, endocrine and biochemical changes, and bone mineral density scans.


RESULTS
Lumbar spine bone mineral density decreased significantly from baseline in the placebo group (-5.1%) but not in the tibolone group (-1.1%). The frequency of hot flushes and sweating episodes was reduced significantly by tibolone. There was no difference between the two treatment groups with regard to the endometriosis scores.


CONCLUSIONS
The addition of tibolone to GnRH-a treatment reduces the bone loss and vasomotor symptoms that normally occur with GnRH-a, thus making long-term treatment with GnRH-a safer and more acceptable. It does not negate the therapeutic effect of GnRH-a on endometriosis.
Lindsay
P C
PC
Royal Free Hospital School of Medicine, London, United Kingdom.
Shaw
R W
RW
Bennink
H J
HJ
Kicovic
P
P
D000328:Adult; D045930:Anabolic Agents / Q000494:pharmacology*; D015519:Bone Density / Q000187:drug effects*; D004311:Double-Blind Method; D004347:Drug Interactions; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy*; D008186:Luteolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D009652:Norpregnenes / Q000494:pharmacology*; D011446:Prospective Studies; D017329:Triptorelin Pamoate / Q000009:adverse effects / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D045930:Anabolic Agents; D008186:Luteolytic Agents; D009652:Norpregnenes; D017329:Triptorelin Pamoate; C027385:tibolone